Prognostic Scoring Index for Patients with Metastatic Pancreatic Adenocarcinoma
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose This study focused on implementation of a prognostic scoring index based on clinico-laboratory parameters measured routinely on admission in metastatic pancreatic cancer patients. Materials and Methods Records from 403 patients of metastatic disease were analyzed retrospectively. Continuous variables were dichotomized according to the normal range or the best cut-off values statistically determined by Contal and O’Quigley method, and then analyzed in association with prognosis—overall survival (OS), using Cox’s proportional hazard model. Scores were calculated by summing the rounded chi-square scores for the factors that emerged in the multivariate analysis. Results Performance status, hemoglobin, leucocyte count, neutrophil-lymphocyte ratio, and carcinoembryonic antigen were independent factors for OS. When patients were divided into three risk groups according to these factors, median survival was 11.7, 6.2, and 1.3 months for the low, intermediate, and high-risk groups, respectively (p < 0.001). Palliative chemotherapy has a significant survival benefit for low and intermediate-risk patients (median OS; 12.5 months vs. 5.9 months, p < 0.001 and 8.0 months vs. 2.0 months, p < 0.001, respectively). Conclusion We advocate the use of a multivariable approach with continuous variables for prognostic modeling. Our index is helpful in accurate patient risk stratification and may aid in treatment selection.
Abstract
Purpose This study focused on implementation of a prognostic scoring index based on clinico-laboratory parameters measured routinely on admission in metastatic pancreatic cancer patients. Materials and Methods Records from 403 patients of metastatic disease were analyzed retrospectively. Continuous variables were dichotomized according to the normal range or the best cut-off values statistically determined by Contal and O’Quigley method, and then analyzed in association with prognosis—overall survival (OS), using Cox’s proportional hazard model. Scores were calculated by summing the rounded chi-square scores for the factors that emerged in the multivariate analysis. Results Performance status, hemoglobin, leucocyte count, neutrophil-lymphocyte ratio, and carcinoembryonic antigen were independent factors for OS. When patients were divided into three risk groups according to these factors, median survival was 11.7, 6.2, and 1.3 months for the low, intermediate, and high-risk groups, respectively (p < 0.001). Palliative chemotherapy has a significant survival benefit for low and intermediate-risk patients (median OS; 12.5 months vs. 5.9 months, p < 0.001 and 8.0 months vs. 2.0 months, p < 0.001, respectively). Conclusion We advocate the use of a multivariable approach with continuous variables for prognostic modeling. Our index is helpful in accurate patient risk stratification and may aid in treatment selection.
참고문헌 (25)
- Ryan DP, "Pancreatic adenocarcinoma", N Engl J Med, 371, pp.2140~2141 (2014)
- Ni XG, "The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer", Eur J Surg Oncol, 31, pp.164~169 (2005)
- Stocken DD, "Modelling prognostic factors in advanced pancreatic cancer", Br J Cancer, 99, pp.883~893 (2008)
- Yi JH, "A prognostic model to predict clinical outcomes with first-line gemcitabine-based chemotherapy in advanced pancreatic cancer", Oncology, 80, pp.175~180 (2011)
- Ciela B., "Hematology in practice" (2011), F.A. Davis Company
- Contal C, "An application of changepoint methods in studying the effect of age on survival in breast cancer", Comput Stat Data Anal, 30, pp.253~270 (1999)
- Eo SH, "K-adaptive partitioning for survival data: the Kaps add-on package for R" (2013), Cornell University Library
- Harrell FE Jr, "Regression models for prognostic prediction : advantages, problems, and suggested solutions", Cancer Treat Rep, 69, pp.1071~1077 (1985)
- Ziske C, "Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine", Br J Cancer, 89, pp.1413~1417 (2003)
- 이경주, "Serum CA 19-9 and CEA Levels as a Prognostic Factor in Pancreatic Adenocarcinoma", Yonsei Medical Journal, 54(3), pp.643~649 (2013), 연세대학교의과대학[DOI]
- Ballehaninna UK, "Serum CA 19-9 as a biomarker for pancreatic cancer : a comprehensive review", Indian J Surg Oncol, 2, pp.88~100 (2011)
- Mazumdar M, "Categorizing a prognostic variable : review of methods, code for easy implementation and applications to decision-making about cancer treatments", Stat Med, 19, pp.113~132 (2000)
- Ballehaninna UK, "The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma : an evidence based appraisal", J Gastrointest Oncol, 3, pp.105~119 (2012)
- Sarraf KM, "Neutrophil", lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer, 2009, pp.137, 425~428
- Walsh SR, "Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer", J Surg Oncol, 91, pp.181~184 (2005)
- Fock RA, "Study of lymphocyte subpopulations in bone marrow in a model of protein-energy malnutrition", Nutrition, 26, pp.1021~1028 (2010)
- Palucka K, "Dendritic cells, inflammation, and breast cancer", Cancer J, 19, pp.511~516 (2013)
- Luo G, "Blood neutrophil-lymphocyte ratio predicts survival in patients with advanced pancreatic cancer treated with chemotherapy", Ann Surg Oncol, 22, pp.670~676 (2015)
- Garcea G, "Preoperative neutrophil-to-lymphocyte ratio(NLR)is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma", World J Surg, 35, pp.868~872 (2011)
- Sugiura T, "Elevated preoperative neutrophil-to-lymphocyte ratio as a predictor of survival after gastroenterostomy in patients with advanced pancreatic adenocarcinoma", Ann Surg Oncol, 20, pp.4330~4337 (2013)
- Hostetter RB, "Carcinoembryonic antigen as a selective enhancer of colorectal cancer metastasis", J Natl Cancer Inst, 82, pp.380~385 (1990)
- Yasue M, "Prognostic values of preoperative and postoperative CEA and CA19.9 levels in pancreatic cancer", Pancreas, 9, pp.735~740 (1994)
- Ruiz-Tovar J, "Identification of prognostic factors in pancreatic cancer", Cir Cir, 79, pp.313~322 (2011)
- Ghaneh P, "Molecular prognostic markers in pancreatic cancer", J Hepatobiliary Pancreat Surg, 9, pp.1~11 (2002)
- 김범석, "Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors", Cancer Research and Treatment, 46(4), pp.323~330 (2014), 대한암학회[DOI]